Regeneron and CureVac: UPC ‘cannot be ignored’

Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unified Patent Court

WATCH: The Unified Patent Court — two years on the frontline

9 December 2025 Will James and Tim Harris, Osborne Clarke, discuss their experiences litigating life sciences cases before the UPC and share key insights from the court’s early decisions.

Unified Patent Court

WATCH: UPC update—shaping patent litigation

4 August 2025 Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.

Unified Patent Court

WATCH: The UPC in practice—optimising your cross-border patent strategy

19 June 2025 Experts from The Broad Institute of MIT and Harvard and McDermott Will & Emery share practical insights on navigating the Unified Patent Court in a cross-border context, in this session from LSPN.

More features

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Regeneron and CureVac: UPC ‘cannot be ignored’

More on this story

Editor's picks

Editor's picks

More features